Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema
MENLO PARK, CA / ACCESSWIRE / April 30, 2024 / Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced final dose administration for the last patient in its U.S...